explore -WSS

explore

author：focus 2025-08-06 04:47:17 - browse：71

Illustration of a teal cancer cell. -- health coverage from STAT — Illustration of a teal cancer cell. Adobe

Sana Biotechnology, a startup that just a couple of years ago raised over $1 billion off a grand plan to create a portfolio of powerful medicines, said Tuesday it would lay off nearly a third of its employees and de-prioritize one of its most ambitious programs as it looks to save money.

The layoffs are Sana’s second round of cuts in less than a year. It laid off 15% of staff last November after axing another program.

Tuesday’s move pushed back a program focused on turning a patient’s own immune cells into cancer-killing assassins or curing blood disorders such as sickle cell with just an IV infusion. Known as in vivo reprogramming, it was originally the company’s central focus and would have amounted to a monumental breakthrough.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Francis Collins on trust in science and how Covid communications failed

hotspot

leisure time

WSS

Prior authorization will have to move faster under new Biden rule

eGenesis tests gene

Virtual care provider acquires bankrupt Pear's prescription apps

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Carvykti CAR

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

hotspot

explore

Wikipedia

Cancer drug shortages should be causing more outrage

New brain studies show LSD's effects on the brain in full color

Walensky prepares to leave CDC — and Congress — behind

My yearlong odyssey to get my son’s ADHD medication covered

Hepatitis C has a cure — but many Americans still lack access to it

Medicare drug price negotiation hasn't dried up venture capital

State Dept. review finds Biden bears some blame for Afghanistan failures

Medicare Advantage today, explained in one chart

At least 13 dead in Texas as scorching temps continue

Copay coupons to count toward deductibles, after Biden court move

leisure time

Prime Medicine, Myeloid Therapeutics clash over genome

Keeping primary care docs in field isn't impossible, says AAFP CEO

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Hospitals owned by private equity see complications spike 25%

Keeping primary care docs in field isn't impossible, says AAFP CEO

HCA sued by state AG for quality issues at Mission Health

hotspot

leisure time

leisure time

focus